Global CDMO for Small Molecule API. AGC Pharma Chemicals, based in Barcelona and Japan, is a company specializing in the development and contract manufacturing of Active Pharmaceutical Ingredients, Small Molecule APIs, and advanced intermediates. We are part of the AGC Group, headquartered in Japan, and we offer an integrated supply chain, with globally coordinated capabilities in Europe and Asia, combined with a strong local presence in Barcelona. This structure allows us to ensure continuity, reliability, and long-term alignment with the needs of our pharmaceutical clients and support projects from the early development stages through to commercial production.

🇬🇧 EN

Ecopol Tech is a polymer science company specialized in Advanced Polymers and Encapsulation Technologies, with strong expertise in water-based polyurethane/polyurea systems and polymeric micro- and nanocapsules.

For the pharmaceutical and dermocosmetic sectors, Ecopol Tech offers its proprietary ECOSTRATAR technology, an advanced encapsulation platform designed to transform sensitive, unstable or difficult-to-formulate active ingredients into stable, multifunctional and high-performance formulations, with potential benefits in active protection, controlled release, delivery, bioavailability, skin penetration and product differentiation. In the cosmetic sector, Ecopol Tech has a registered INCI ingredient, POLYURETHANE CROSSPOLYMER-1, and commercializes both advanced polymers and encapsulated systems containing cosmetic active ingredients.

The ECOSTRATAR technology has been validated through proof-of-concept studies across different application areas, including oncology, antibacterial applications, regenerative medicine, immunology and cardiovascular diseases, offering active ingredient protection, controlled release and advanced cosmetic/dermocosmetic formulations. The oncology application of the ECOSTRATAR technology has been licensed to Polar NanoPharma  (www.polarnanopharma.com), a spin-off of Ecopol Tech focused on the development of nanoparticle-based therapies for cancer.
____________________________________________________________________________________________

🇪🇸 ES

Ecopol Tech es una empresa de ciencia de polímeros especializada en Advanced Polymers y Encapsulation Technologies, con una sólida experiencia en sistemas acuosos de poliuretano/poliurea y micro- y nanocápsulas poliméricas.

Para los sectores farmacéutico y dermocosmético, Ecopol Tech ofrece su tecnología propietaria ECOSTRATAR, una plataforma avanzada de encapsulación diseñada para transformar activos sensibles, inestables o difíciles de formular en formulaciones estables, multifuncionales y de alto rendimiento, con potencial para mejorar la protección del activo, la liberación controlada, el delivery, la biodisponibilidad, la penetración cutánea y la diferenciación del producto. En el sector cosmético, Ecopol Tech cuenta con un ingrediente INCI registrado, POLYURETHANE CROSSPOLYMER-1, y comercializa tanto polímeros avanzados como sistemas encapsulados con activos cosméticos.

La tecnología ECOSTRATAR ha sido validada mediante estudios de prueba de concepto en distintas áreas de aplicación, incluyendo oncología, aplicaciones antibacterianas, medicina regenerativa, inmunología y enfermedades cardiovasculares, ofreciendo protección de ingredientes activos, liberación controlada y formulaciones cosméticas/dermocosméticas avanzadas. La aplicación de la tecnología ECOSTRATAR en oncología ha sido licenciada a Polar NanoPharma (www.polarnanopharma.com), una spin-off de Ecopol Tech centrada en el desarrollo de terapias nanoparticuladas frente al cáncer.

At Flavii, we are committed to making epigenetic treatments available for patients suffering from brain disorders. We strongly believe that by harnessing the power of epigenetic modulation, we can develop transformative therapies that meaningfully improve the lives of patients and their families, while addressing high unmet medical needs in neurology.

Market Acces Services

Integra Therapeutics is a biotechnology company pioneering the next generation of gene-writing tools to develop curative treatments for genetic, oncological, and autoimmune diseases with high unmet medical needs. By addressing the major technical bottlenecks in the Cell and Gene Therapy (CGT) space, we aim to improve the scope, efficiency, and safety of advanced therapies.

At the core of our innovation is FiCAT (Find Cut and Transfer), a proprietary, state-of-the-art gene-writing platform engineered to overcome the main limitations of current gene therapies: payload size, integration precision, and genomic stability. FiCAT elegantly combines the pinpoint targeting precision of the CRISPR-Cas system with the highly efficient cargo transfer capabilities of an engineered piggyBac transposase. This unique mechanism allows for the safe and highly efficient targeted integration of both small and exceptionally large therapeutic DNA payloads into the genome.

Leveraging the versatility of the FiCAT platform, Integra Therapeutics is advancing a robust pipeline spanning both in vivo and ex vivo applications. Our development programs include a lead in vivo gene therapy project, alongside multiple highly promising ex vivo and in vivo cell therapy programs focused on next-generation CAR-T. By unlocking new possibilities in targeted DNA insertion, we are committed to delivering life-changing, durable genetic medicines to patients.

CDMO specilized in small molecules with 7 manufacturing sites and 2 R&D Centers, all located in Europe.

Moehs can cover the full lifecycle of the molecule, starting in pre-clinical, clinical phases and comercial launch.

Nanobots Therapeutics is a biotech company focused on developing and commercializing MotionTx platform.

MotionTx technology enables the development of nanobots: unique therapeutic entities that penetrate tissues with superior efficacy, enhancing drug accumulation in target cells.  

NEMA HEALTH is a preclinical stage biotech company that is developing a therapeutic vaccine for cancer treatment with main focus on advance melanoma and expanding to other types of cancer. 

A family of immunoestimulatory in-licensed peptides is the core technology behind the therapeutic vaccine.

Nuage Therapeutics is pioneering a novel drug discovery approach which allows the targeting of intrinsically disordered proteins (IDPs). Our mission is to deliver a new wave of transformational precision therapies for aggressive cancers. Nuage's pioneering approach enables the development of innovative therapies against cancer-driving transcription factors. 

Peptomyc is a spin-off from the Vall d’Hebron Institute of Oncology (VHIO) that is revolutionizing cancer treatment: we are the only company that uses mini-protein therapeutics to directly inhibit MYC – the central engine for cancer proliferation, survival, and resistance to treatment. Doing so, Peptomyc offers a foundational treatment to any cancer patient with abnormal MYC activity, improving patient’ survival and quality of life.